Big Money Sentiment increased to 1.53 in 2018 Q2. It has change of 0.64, from 2018Q1’s 0.89. The ratio is positive due to PTLA positioning: 16 sold and 46 reduced. 35 funds amassed positions and 60 increased positions. Investors holded 55.00 million in 2018Q1 but now own 60.58 million shares or 10.15% more. Vanguard Gp owns 5.67 million shs. Highland Mngmt Ltd Partnership invested 1.5% of its capital in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Pinnacle accumulated 359,995 shs or 0.28% of the stock. Citigroup Inc reported 89,491 shs. Moreover, Prudential Fincl Inc has 0% invested in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) for 83,782 shs. Amer Century Companies, Missouri-based fund reported 80,698 shs. Stifel Corporation owns 7,453 shs for 0% of their capital. State Board Of Administration Of Florida Retirement accumulated 0% or 32,408 shs. Loring Wolcott And Coolidge Fiduciary Advsr Ltd Liability Partnership Ma holds 10 shs. Pictet Asset Mgmt Ltd invested in 582,426 shs. Alps Inc reported 72,306 shs stake. Ameritas Ptnrs Incorporated stated it has 0.01% of its capital in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Walleye Trading Limited Liability Company has 0% invested in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Sg Americas Securities Limited Liability Co holds 0% or 3,739 shs in its capital. Goldman Sachs Grp Incorporated reported 419,932 shs.
PTLA registered $9.85 million net activity with 1 buy and 1 insider sale since June 6, 2018. On Wednesday, June 6 Lis William sold $231,159 worth of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA).
Partner Fund Management Lp’s stake in Portola Pharmaceuticals Inc (PTLA) is reduced by 4.64% based on its latest 2018Q2 regulatory filing with the SEC. The company’s stock sank 29.38% while Partner Fund Management Lp sold 246,901 shares. The health care company at the end of 2018Q2 was valued at $191.86 million. It’s down from 5.33M at the end of the previous reported quarter. Now it had 5.08M shares held by the hedge fund . $1.45B is the MC of Portola Pharmaceuticals Inc. The stock decreased 5.14% or $1.19 during the last trading session, reaching $21.95.Portola Pharmaceuticals, Inc. has 1.94 million shares volume, 19.31% up from normal. PTLA is downtrending and has moved 48.89% since November 10, 2017. The stock underperformed the S&P500 by 64.51%.
About $6.39B US Long portfolio Partner Fund Management Lp operates. According to a filing the fund rose its stake in Alder Biopharmaceuticals Inc (Prn) by 14.64 million shares to 32.41M shares, valued at $33.75 million in 2018Q2. For a total of 1.24 million shares it increased its holding in Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) by 103,379 shares in the quarter, and has risen its stake in Dropbox Inc.
For more Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) news published briefly go to: Nasdaq.com, Streetinsider.com, Benzinga.com, Nasdaq.com or Benzinga.com. The titles are as follows: “Mid-Day Market Update: Dow Turns Higher; Koppers Holdings Shares Drop Following Weak Q3 Results” published on November 08, 2018, “Pre-Open Movers 11/08: (CVNA) (PTLA) (CYBR) Higher; (VYGR) (KRO) (ZAYO) Lower (more…)” on November 08, 2018, “65 Stocks Moving In Thursday’s Mid-Day Session” with a publish date: November 08, 2018, “Portola Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update” and the last “80 Biggest Movers From Yesterday” with publication date: November 09, 2018.
Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Ratings Coverage
In total 4 analysts cover Portola Pharma (NASDAQ:PTLA). “Buy” rating has 2, “Sell” are 0, while 2 are “Hold”. 50% are bullish. 7 are the (NASDAQ:PTLA)’s analyst reports since May 17, 2018 according to StockzIntelligence Inc. On Friday, August 10 Citigroup maintained Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) with “Buy” rating. In Thursday, November 8 report Credit Suisse maintained the stock with “Neutral” rating. On Thursday, October 11 the firm earned “Equal-Weight” rating by Morgan Stanley. On Monday, August 13 Morgan Stanley maintained Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) with “Equal-Weight” rating. On Friday, August 10 the rating was downgraded by Credit Suisse to “Underperform”. In Thursday, May 17 report Oppenheimer maintained it with “Buy” rating and $8000 target. On Monday, August 27 the rating was upgraded by Credit Suisse to “Neutral”.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.